APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide and Oligonucleotide Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Peptide and Oligonucleotide Drugs Industry Research Report 2026

28 December 2025131 pages

Choose your research edition.

Industry ResearchPeptide and Oligonucleotide Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide and Oligonucleotide Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peptide and Oligonucleotide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide and Oligonucleotide Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide and Oligonucleotide Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Peptide and Oligonucleotide Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Peptide and Oligonucleotide Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Peptide and Oligonucleotide Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Peptide and Oligonucleotide Drugs include Takeda, Sanofi, Novartis, Roche, Lilly, SciClone Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku and Moderna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Peptide and Oligonucleotide Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Peptide and Oligonucleotide Drugs Market by Company

Takeda

Sanofi

Novartis

Roche

Lilly

SciClone Pharmaceuticals

Sarepta Therapeutics

Nippon Shinyaku

Moderna

MiNA Therapeutics

Merck Serono

Ipsen PHarma Biotech

Ionis

Ferring Pharmaceuticals

BioNTech

AstraZeneca

Asahi Kasei

Alnylam

Peptide and Oligonucleotide Drugs Segment by Type

Oligonucleotide Drugs

Peptide Drugs

Peptide and Oligonucleotide Drugs Segment by Application

Oncology Drugs

Digestive system Drugs

Immunomodulatory Drugs

Bone and Connective Tissue Types

Other

Peptide and Oligonucleotide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide and Oligonucleotide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide and Oligonucleotide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide and Oligonucleotide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Peptide and Oligonucleotide Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Peptide and Oligonucleotide Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Peptide and Oligonucleotide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Peptide and Oligonucleotide Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Peptide and Oligonucleotide Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Peptide and Oligonucleotide Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Peptide and Oligonucleotide Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Peptide and Oligonucleotide Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Peptide and Oligonucleotide Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Peptide and Oligonucleotide Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Peptide and Oligonucleotide Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Peptide and Oligonucleotide Drugs, Product Type & Application Table 14. Global Peptide and Oligonucleotide Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Peptide and Oligonucleotide Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Company Information Table 19. Takeda Business Overview Table 20. Takeda Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Peptide and Oligonucleotide Drugs Product Portfolio Table 22. Takeda Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanofi Peptide and Oligonucleotide Drugs Product Portfolio Table 27. Sanofi Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Peptide and Oligonucleotide Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Roche Peptide and Oligonucleotide Drugs Product Portfolio Table 37. Roche Recent Developments Table 38. Lilly Company Information Table 39. Lilly Business Overview Table 40. Lilly Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Lilly Peptide and Oligonucleotide Drugs Product Portfolio Table 42. Lilly Recent Developments Table 43. SciClone Pharmaceuticals Company Information Table 44. SciClone Pharmaceuticals Business Overview Table 45. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 47. SciClone Pharmaceuticals Recent Developments Table 48. Sarepta Therapeutics Company Information Table 49. Sarepta Therapeutics Business Overview Table 50. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 52. Sarepta Therapeutics Recent Developments Table 53. Nippon Shinyaku Company Information Table 54. Nippon Shinyaku Business Overview Table 55. Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio Table 57. Nippon Shinyaku Recent Developments Table 58. Moderna Company Information Table 59. Moderna Business Overview Table 60. Moderna Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Moderna Peptide and Oligonucleotide Drugs Product Portfolio Table 62. Moderna Recent Developments Table 63. MiNA Therapeutics Company Information Table 64. MiNA Therapeutics Business Overview Table 65. MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 67. MiNA Therapeutics Recent Developments Table 68. Merck Serono Company Information Table 69. Merck Serono Business Overview Table 70. Merck Serono Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio Table 72. Merck Serono Recent Developments Table 73. Ipsen PHarma Biotech Company Information Table 74. Ipsen PHarma Biotech Business Overview Table 75. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio Table 77. Ipsen PHarma Biotech Recent Developments Table 78. Ionis Company Information Table 79. Ionis Business Overview Table 80. Ionis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Ionis Peptide and Oligonucleotide Drugs Product Portfolio Table 82. Ionis Recent Developments Table 83. Ferring Pharmaceuticals Company Information Table 84. Ferring Pharmaceuticals Business Overview Table 85. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 87. Ferring Pharmaceuticals Recent Developments Table 88. BioNTech Company Information Table 89. BioNTech Business Overview Table 90. BioNTech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. BioNTech Peptide and Oligonucleotide Drugs Product Portfolio Table 92. BioNTech Recent Developments Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio Table 97. AstraZeneca Recent Developments Table 98. Asahi Kasei Company Information Table 99. Asahi Kasei Business Overview Table 100. Asahi Kasei Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio Table 102. Asahi Kasei Recent Developments Table 103. Alnylam Company Information Table 104. Alnylam Business Overview Table 105. Alnylam Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Alnylam Peptide and Oligonucleotide Drugs Product Portfolio Table 107. Alnylam Recent Developments Table 108. Global Peptide and Oligonucleotide Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026) & (K Units) Table 110. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021-2026) Table 111. Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032) & (K Units) Table 112. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2027-2032) Table 113. Global Peptide and Oligonucleotide Drugs Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021-2026) Table 115. Global Peptide and Oligonucleotide Drugs Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2027-2032) Table 117. North America Peptide and Oligonucleotide Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 119. North America Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 120. North America Peptide and Oligonucleotide Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Peptide and Oligonucleotide Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Peptide and Oligonucleotide Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 124. Europe Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 125. Europe Peptide and Oligonucleotide Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Peptide and Oligonucleotide Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 129. Asia Pacific Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 130. Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Peptide and Oligonucleotide Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 134. South America Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 135. South America Peptide and Oligonucleotide Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Peptide and Oligonucleotide Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 143. Global Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 144. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2026) Table 145. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2027-2032) Table 146. Global Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2026) Table 149. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2027-2032) Table 150. Global Peptide and Oligonucleotide Drugs Price by Type (2021-2026) & (US$/Unit) Table 151. Global Peptide and Oligonucleotide Drugs Price by Type (2027-2032) & (US$/Unit) Table 152. Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 153. Global Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 154. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2026) Table 155. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2027-2032) Table 156. Global Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2026) Table 159. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2027-2032) Table 160. Global Peptide and Oligonucleotide Drugs Price by Application (2021-2026) & (US$/Unit) Table 161. Global Peptide and Oligonucleotide Drugs Price by Application (2027-2032) & (US$/Unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Peptide and Oligonucleotide Drugs Distributors List Table 165. Peptide and Oligonucleotide Drugs Customers List Table 166. Peptide and Oligonucleotide Drugs Industry Trends Table 167. Peptide and Oligonucleotide Drugs Industry Drivers Table 168. Peptide and Oligonucleotide Drugs Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Peptide and Oligonucleotide Drugs Product Image Figure 5. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Peptide and Oligonucleotide Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Peptide and Oligonucleotide Drugs Sales (2021-2032) & (K Units) Figure 8. Global Peptide and Oligonucleotide Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Oligonucleotide Drugs Product Image Figure 10. Peptide Drugs Product Image Figure 11. Oncology Drugs Product Image Figure 12. Digestive system Drugs Product Image Figure 13. Immunomodulatory Drugs Product Image Figure 14. Bone and Connective Tissue Types Product Image Figure 15. Other Product Image Figure 16. Global Peptide and Oligonucleotide Drugs Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Peptide and Oligonucleotide Drugs, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Peptide and Oligonucleotide Drugs Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Peptide and Oligonucleotide Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Peptide and Oligonucleotide Drugs Sales by Region in 2025 Figure 22. Global Peptide and Oligonucleotide Drugs Revenue by Region in 2025 Figure 23. North America Peptide and Oligonucleotide Drugs Market Size by Country in 2025 Figure 24. North America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032) Figure 25. North America Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021-2032) Figure 26. United States Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Peptide and Oligonucleotide Drugs Market Size by Country in 2025 Figure 30. Europe Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032) Figure 31. Europe Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021-2032) Figure 32. Germany Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Peptide and Oligonucleotide Drugs Market Size by Country in 2025 Figure 43. Asia Pacific Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021-2032) Figure 45. China Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Peptide and Oligonucleotide Drugs Market Size by Country in 2025 Figure 54. South America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032) Figure 55. South America Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021-2032) Figure 56. Brazil Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country in 2025 Figure 60. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Peptide and Oligonucleotide Drugs Revenue Market Share by Country (2021-2032) Figure 62. Egypt Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Peptide and Oligonucleotide Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2032) Figure 68. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2032) Figure 69. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Type (2021-2032) Figure 70. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2032) Figure 71. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2032) Figure 72. Global Peptide and Oligonucleotide Drugs Price (US$/Unit) by Application (2021-2032) Figure 73. Peptide and Oligonucleotide Drugs Value Chain Figure 74. Peptide and Oligonucleotide Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Oligonucleotide Drugs
  • Peptide Drugs
Applications
  • Oncology Drugs
  • Digestive system Drugs
  • Immunomodulatory Drugs
  • Bone and Connective Tissue Types
  • Other
Companies covered
  • Takeda
  • Sanofi
  • Novartis
  • Roche
  • Lilly
  • SciClone Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Moderna
  • MiNA Therapeutics
  • Merck Serono
  • Ipsen PHarma Biotech
  • Ionis
  • Ferring Pharmaceuticals
  • BioNTech
  • AstraZeneca
  • Asahi Kasei
  • Alnylam

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Peptide and Oligonucleotide Drugs Market Size (2021-2032)
  4. 2.2.2 Global Peptide and Oligonucleotide Drugs Sales (2021-2032)
  5. 2.2.3 Global Peptide and Oligonucleotide Drugs Market Average Price (2021-2032)
  6. 2.3 Peptide and Oligonucleotide Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Oligonucleotide Drugs
  9. 2.3.3 Peptide Drugs
  10. 2.4 Peptide and Oligonucleotide Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Oncology Drugs
  13. 2.4.3 Digestive system Drugs
  14. 2.4.4 Immunomodulatory Drugs
  15. 2.4.5 Bone and Connective Tissue Types
  16. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Peptide and Oligonucleotide Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Peptide and Oligonucleotide Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Peptide and Oligonucleotide Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Peptide and Oligonucleotide Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Peptide and Oligonucleotide Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Peptide and Oligonucleotide Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Peptide and Oligonucleotide Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Peptide and Oligonucleotide Drugs, Established Date
  9. 3.9 Global Peptide and Oligonucleotide Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda
  2. 4.1.1 Takeda Company Information
  3. 4.1.2 Takeda Business Overview
  4. 4.1.3 Takeda Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Peptide and Oligonucleotide Drugs Product Portfolio
  6. 4.1.5 Takeda Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Peptide and Oligonucleotide Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche Peptide and Oligonucleotide Drugs Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 Lilly
  26. 4.5.1 Lilly Company Information
  27. 4.5.2 Lilly Business Overview
  28. 4.5.3 Lilly Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Lilly Peptide and Oligonucleotide Drugs Product Portfolio
  30. 4.5.5 Lilly Recent Developments
  31. 4.6 SciClone Pharmaceuticals
  32. 4.6.1 SciClone Pharmaceuticals Company Information
  33. 4.6.2 SciClone Pharmaceuticals Business Overview
  34. 4.6.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  36. 4.6.5 SciClone Pharmaceuticals Recent Developments
  37. 4.7 Sarepta Therapeutics
  38. 4.7.1 Sarepta Therapeutics Company Information
  39. 4.7.2 Sarepta Therapeutics Business Overview
  40. 4.7.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  42. 4.7.5 Sarepta Therapeutics Recent Developments
  43. 4.8 Nippon Shinyaku
  44. 4.8.1 Nippon Shinyaku Company Information
  45. 4.8.2 Nippon Shinyaku Business Overview
  46. 4.8.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
  48. 4.8.5 Nippon Shinyaku Recent Developments
  49. 4.9 Moderna
  50. 4.9.1 Moderna Company Information
  51. 4.9.2 Moderna Business Overview
  52. 4.9.3 Moderna Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Moderna Peptide and Oligonucleotide Drugs Product Portfolio
  54. 4.9.5 Moderna Recent Developments
  55. 4.10 MiNA Therapeutics
  56. 4.10.1 MiNA Therapeutics Company Information
  57. 4.10.2 MiNA Therapeutics Business Overview
  58. 4.10.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  60. 4.10.5 MiNA Therapeutics Recent Developments
  61. 4.11 Merck Serono
  62. 4.11.1 Merck Serono Company Information
  63. 4.11.2 Merck Serono Business Overview
  64. 4.11.3 Merck Serono Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
  66. 4.11.5 Merck Serono Recent Developments
  67. 4.12 Ipsen PHarma Biotech
  68. 4.12.1 Ipsen PHarma Biotech Company Information
  69. 4.12.2 Ipsen PHarma Biotech Business Overview
  70. 4.12.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
  72. 4.12.5 Ipsen PHarma Biotech Recent Developments
  73. 4.13 Ionis
  74. 4.13.1 Ionis Company Information
  75. 4.13.2 Ionis Business Overview
  76. 4.13.3 Ionis Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Ionis Peptide and Oligonucleotide Drugs Product Portfolio
  78. 4.13.5 Ionis Recent Developments
  79. 4.14 Ferring Pharmaceuticals
  80. 4.14.1 Ferring Pharmaceuticals Company Information
  81. 4.14.2 Ferring Pharmaceuticals Business Overview
  82. 4.14.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  84. 4.14.5 Ferring Pharmaceuticals Recent Developments
  85. 4.15 BioNTech
  86. 4.15.1 BioNTech Company Information
  87. 4.15.2 BioNTech Business Overview
  88. 4.15.3 BioNTech Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
  90. 4.15.5 BioNTech Recent Developments
  91. 4.16 AstraZeneca
  92. 4.16.1 AstraZeneca Company Information
  93. 4.16.2 AstraZeneca Business Overview
  94. 4.16.3 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
  96. 4.16.5 AstraZeneca Recent Developments
  97. 4.17 Asahi Kasei
  98. 4.17.1 Asahi Kasei Company Information
  99. 4.17.2 Asahi Kasei Business Overview
  100. 4.17.3 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
  102. 4.17.5 Asahi Kasei Recent Developments
  103. 4.18 Alnylam
  104. 4.18.1 Alnylam Company Information
  105. 4.18.2 Alnylam Business Overview
  106. 4.18.3 Alnylam Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
  108. 4.18.5 Alnylam Recent Developments
5 Global Peptide and Oligonucleotide Drugs Market Scenario by Region
  1. 5.1 Global Peptide and Oligonucleotide Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Peptide and Oligonucleotide Drugs Sales by Region: 2027-2032
  5. 5.3 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Peptide and Oligonucleotide Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Peptide and Oligonucleotide Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Peptide and Oligonucleotide Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Peptide and Oligonucleotide Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Peptide and Oligonucleotide Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Peptide and Oligonucleotide Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Peptide and Oligonucleotide Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Peptide and Oligonucleotide Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Peptide and Oligonucleotide Drugs Value Chain Analysis
  2. 8.1.1 Peptide and Oligonucleotide Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Peptide and Oligonucleotide Drugs Production Mode & Process
  5. 8.2 Peptide and Oligonucleotide Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Peptide and Oligonucleotide Drugs Distributors
  8. 8.2.3 Peptide and Oligonucleotide Drugs Customers
9 Global Peptide and Oligonucleotide Drugs Analyzing Market Dynamics
  1. 9.1 Peptide and Oligonucleotide Drugs Industry Trends
  2. 9.2 Peptide and Oligonucleotide Drugs Industry Drivers
  3. 9.3 Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges
  4. 9.4 Peptide and Oligonucleotide Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst